Opportunistic infections update.
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D004347:Drug Interactions; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy; D006509:Hepatitis B / Q000188:drug therapy*; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D019259:Lamivudine / Q000627:therapeutic use*; D008099:Liver / Q000187:drug effects; D012254:Ribavirin / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D000998:Antiviral Agents; D016898:Interferon-alpha; D019259:Lamivudine; D012254:Ribavirin